Nucleome Therapeutics (\u2018Nucleome\u2019 or \u2018the Company\u2019), a biotechnology company using spatial genomics to discover precision medicines for complex diseases, announces today that it has appointed Dr. Mark Bodmer as Chief Executive Officer with effect from 24 July.
Agricultural biotech firm Moa Technology has signed a research and commercial partnership with Nufarm, a global agricultural innovator based in Melbourne, Australia.
In April 2024, the BioEscalator welcomed Granza Bio, a biotech startup focusing on developing novel immunotherapy delivery methods. The company has already attracted investor interest and closed a successful $7.14 million seed funding round led by Felicis and Refactor, with participation from Y Combinator.
Our Business Manager, Dr Claire Shingler, participated in a collaborative project highlighting the strong partnerships between academic and industry professionals in the Medical Sciences Division. In this project, Claire shared her story and discussed her role in managing Oxford's biomedical science incubator. She discussed her motivations and the rewarding experiences she has had in supporting innovative spin-outs.
The idea behind antibacterial company OSPT came to CEO and Founder Stephanie Lesage as she talked to haemodialysis patients as part of a research project, when it became clear to her that they had a really deep fear of the development of infection via their catheters. Their concerns were so significant that they almost outweighed the benefits of the dialysis treatment in the patients\u2019 minds.
Ochre and GSK will create a foundational liver biology dataset that could have the potential to further improve translation of novel therapies for liver diseases.
Former BioEscalator tenant Alchemab Therapeutics continues to make significant strides in Parkinson's disease research, recently receiving a substantial grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to advance its innovative antibody discovery program.
MediMab Biotherapeutics announces its graduation from the BioEscalator. This move represents a major milestone for the company as it relocates to Abingdon Science Park, positioning itself for further expansion and cutting-edge research in immuno-oncology.
A seminal study in The Lancet\u00b9 estimates that in 2019 some 4.95 million deaths were associated with bacterial AMR, including 1.27 million deaths attributable to bacterial AMR. Evolvere is tackling this challenging unmet need using a platform combining synthetic biology, bioinformatics, and AI, designing new drugs plus generating AI models for other companies to license.
The BioEscalator welcomes CardiaTec, a spin-out company from the University of Cambridge that employs computational methods to decode the biology behind cardiovascular disease.
Two clocks are visible behind the Chief Scientific Officer of MediMabBio, Dr Chris Willberg, as he sits in the company office at the BioEscalator \u2013 showing time zones seven hours apart, they are a reminder of how teams in Seoul and Oxford are working together to discover new treatments for cancer and autoimmune disease.
The BioEscalator is pleased to welcome Granza Bio, a biotech startup founded by two PhD graduates in oncology and immunology from the University of Oxford. Granza Bio is pioneering a new era in cancer therapeutics by developing personalised and targeted cancer treatments using the body's own immune system.
Companies start in all kinds of different ways, and for Bioarchitech it was brainstorming that generated the idea behind the enterprise. It is now planning a Series A fundraising to bring its lead candidate to the clinic. Bioarchitech is focused on cancer, developing oncolytic viruses encoding protein immunotherapies for the destruction of tumours, ideally with just one or two doses.
Exogene, a pioneer in the use of generative artificial intelligence (AI) for T-cell receptor (TCR) engineering, has entered into a research collaboration with industry leader Immunocore Holdings plc (NASDAQ: IMCR), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases.
The OBN Awards recognise companies that demonstrate outstanding leadership, innovative practices, and significant contributions towards addressing clinical needs at different stages of development.
The BioEscalator recently marked its 5th anniversary with a celebration that showcased the impressive journeys of some of its current and graduated biotech companies.
![](\"https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-appoints-mark-bodmer-as-chief-executive-officer/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n